A Multicentric, open label randomised controlled phase II/III study to evaluate the Safety and Immunogenicity of BES Inactivated JE vaccine in healthy greater than or equal to 1 TO 3 year old Indian children.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IC 51 (Primary) ; Japanese encephalitis vaccine
Indications Japanese encephalitis
Focus Adverse reactions; Pharmacodynamics; Registrational

Most Recent Events

16 Sep 2011 The study met its primary endpoint, as reported in an Intercell and Biological E Limited media release.
16 Sep 2011 Status changed from active, no longer recruiting to completed, as reported in an Intercell and Biological E Limited media release.
16 Aug 2011 Biological E is moving towards submission for licensure in India, with a planned launch in 2012, according to an Intercell media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight